

Date: 25th July, 2025

To,
BSE Limited
Department of Corporate Services
P. J. Towers,
Dalal Street, Fort,
Mumbai – 400001.
Scrip Code: 511523

Sub: **Press Release on Receipt of Regulatory Approval and first commercial order from Leading Marketplace Company**

Dear Sir/ Madam,

We are enclosing herewith the Press Release on receipt of regulatory approval and first commercial order from leading marketplace Company.

We request you to kindly take the same on record.

Thanking You.

Yours truly,
For **Veerhealth Care Limited**

Bhavin S. Shah
Managing Director
DIN: 03129574





Veerhealth Care Limited announces Regulatory Approval and first commercial Trial order from India's Leading Marketplace Company.

Mumbai – 25th July 2025: Veerhealth Care Limited (BSE: VEERHEALTH), Ayuveer, backed by Veerhealth Care's expertise in Ayurveda, specializes in crafting ayurvedic medicines and oral care products with natural ingredients. With a focus on quality and affordability, Ayuveer aims to offer an exceptional and safe daily care experience to its customers.

Veerhealth Care has received mandatory regulatory approval from the Food and Drug Authority, Gujarat for manufacturing and supply of personal care products for this India's leading marketplace company.

Veerhealth Care had recently entered into a strategic Contract Manufacturing Agreement with a company having top position in personal care segment on marketplace companies in the country for the production of its private-label personal care range of products. This Order is from this client for manufacture and supply of products in personal care category. This order is for products in skin care and face care segment and going forward more products would be added to the contract manufacturing portfolio. The Order is worth around ₹0.48 Crores to be executed in 30 days.

Commenting on the achievement, Mr. Bhavin Shah - Managing Director of Veerhealth Care Limited, said, "I am delighted to share this milestone achievement of securing Regulatory approval & significant order from India's Leading Marketplace Company which not only boosts the company's current standing but also enhances its reputation and visibility in the market. The Company is expected to get repeat orders from this client for its skin care and face care segment. It's a testament to the quality of our products & services. Building a strong relationship with this client could further lead to more opportunities and larger orders down the line.

In F.Y. 2025-26 we are expecting Total Revenues of ₹ 35-40 crores with PAT of 10%.

To meet the increased demand from both Domestic and Export clients, Company has started operating at Full capacity which will help in reducing the overall costs and boosting Total Income and PAT. **In coming Quarters, we expect to more than fully recover the reduction in Total Income and PAT caused by USFDA Inspection as Company has started dispatching for Exports. We are expecting to get USFDA clearance for Medical devices category."**

Products / Services offered by Veerhealth Care:

1. **Contract Manufacturing** – Veerhealth Care manufacture products on behalf of Brands to meet their requirements. The Brands give the Company specifications about the products to be manufactured.
2. **White Labelling** – Veerhealth Care manufactures generic products that retailers can sell under their own Brands.
3. **Product Research & Development** – Veerhealth Care has extensive in-house R&D facility for designing, testing and manufacturing. Company has the capability of creating various new products. Till now Company has launched more than 100 products through this. The Company sells its products under the Brand "Ayuveer".
4. **Customised Product Formulations** – Veerhealth Care has the capability of manufacturing specialised product formulations customised for the Brands. Due to customisation the products can meet the standard specifications of the Brands.

Veerhealth Care has established a new division focused on hospital care, which includes partnering with a leading manufacturer and exporter of medical equipment. This new division will offer a range of equipment, including ventilators, defibrillators, infusion pumps, syringe pumps, and other accessories. Company intends to supply these products to government organizations and hospitals.

VeerPlast is a division of Veerhealth Care Limited. It is a plastic molding company, providing high-quality plastic products and services to various industries. At VeerPlast, Company takes pride in being a leading manufacturer of high-quality toothbrushes, dedicated to promoting superior oral hygiene through innovation, precision, and commitment to excellence. With years of expertise in plastic molding and toothbrush manufacturing, Company ensures that each product delivers exceptional comfort, durability, and cleaning efficiency.

About The Company

VeerHealth Care Limited (BSE – 511523) is involved in the business of manufacturing and supply of Ayurvedic medicines, oral care products & personal care products. All its finished formulations are manufactured in their own state-of-the-art manufacturing facility at Vapi, Gujarat designed to comply with international requirements with validated systems. The Company produces Intensive research based quality products with Expert guidance and enormous experience of renowned Vaidya of Mumbai, Dr. Vinod C. Mehta, an Ayurvedic Practitioner for 30 years and Dr. Rajiv Bhirud, an expert in formulations of cosmetic and personal care products. Some of its products are Health Care, Oral Care & Personal Care products like Shampoos, Conditioners, Lipbalm, Creams, Scrubs, Bath Salts, Shower Gels, Lotions, Ayurvedic Toothpaste & much more under Ayurvedic & Cosmetic License. Manufacturing Certifications: Ayurvedic Mfg. License, Ayurvedic GMP, Cosmetic Mfg. License, Cosmetic GMP, ISO 9001: 2015, Authorized Economic Operator T1 Certificate (Exporter) and Certification of Registration US FDA Labeler Code.

Veerhealth Care Limited specializes in manufacturing of Pure Vegetarian toothpaste.

The company is expecting to reach Revenue of ₹ 100 crores with PAT of 10% in next 24 to 36 months.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.